Renal failure in patients with cirrhosis and ascites: Incidence, etiology and predictive factors;Insuficiencia renal en pacientes con cirrosis y ascitis: Incidencia, etiología y factores predictivos

Acta Gastroenterologica Latinoamericana

Volumn 38, Issue 2, 2008, Pages 116-125

  Alfonso Mathurin, Sebastián ^a,b,c   Jaimet, Celia ^a   Turletti, Carolina ^a   Arosio, Andrea ^a   González, Guadalupe ^a   Kuzmicz, Gisela ^a  

^a Hospital I Carrasco   (Argentina)

^b UAI

^c NONE   (Argentina)

Author keywords

Ascites; Cirrhosis; Hepatorrenal syndrome; Renal failure

Indexed keywords

BIOLOGICAL MARKER;

ADULT; AGED; ARTICLE; ASCITES; BLOOD; EPIDEMIOLOGY; FEMALE; FIBROSIS; HEPATORENAL SYNDROME; HUMAN; KIDNEY FAILURE; MALE; MIDDLE AGED; MORTALITY; PROGNOSIS;

ADULT; AGED; ASCITES; BIOLOGICAL MARKERS; EPIDEMIOLOGIC METHODS; FEMALE; FIBROSIS; HEPATORENAL SYNDROME; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; RENAL INSUFFICIENCY;

EID: 45749097058     PISSN: 03009033     EISSN: 03009033     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Arroyo V, Ginès P, Gerbes AL, Dudley FJ, Gentilini P, Laffi G, Reynolds TB, Ring-Larsen H, Schölmerichs J. Definition and diagnostic criteria of refractory ascites and hepatorrenal syndrome in cirrhosis. International Ascites Club. Hepatology 1996;23:164-176.
2. Ginés A, Escorsell A, Ginès P, Salo J, Jiménez W, Inglada L, Navasa M Claria J, Rimola A, Arroyo V, Rodrés J. Incidence, predictive factors, and prognosis of the hepatorrenal syndrome in cirrhosis with ascites. Gastroenterology 1993;105:229-236.
3. Moreau R, Lebrec D. Review article: hepatorrenal syndrome - definitions and diagnosis. Aliment Pharmacol Ther 2004; 20:24-28.
4. Salerno F, Gerbes A, Gines P, Wong F, Arroyo V. Diagnosis, prevention and treatment of hepatorrenal syndrome in cirrhosis. A consensus workshop of the international ascites club. Gut 2007;56:1310-1318.
5. Wong F. Treatment of hepatorrenal syndrome. Indian J Gastroenterol 2006;25:8-12.
6. Thadhani R, Pascual M, Bonventre J. Acute renal failure. N Engl J Med 1996;334:1448-1460.
7. Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA, Schein RM, Sibbald WJ. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest 1992;101:1644-1655.
8. Forrest EH, Evans CDJ, Stewart S, Philips M, Oo YH, McAvoy NC, Fisher NC, Singhal S, Brind A, Haydon G, O'Grady J, Day CP, Hayes PC, Murray LS, Morris AJ. Analysis of factors predictive of mortality in alcoholic hepatitis and derivation and validation of de Glasgow alcoholic hepatitis score. Gut 2005;54:1174-1179.
9. Kulkarni K, Tran T, Medrano M, Yoffe B, Goodgame R. The role of the discriminant factor in the assessment and treatment of alcoholic hepatitis. J Clin Gastroenterol 2004;38:453-459.
10. Wu CC, Yeung LK, Tsai WS, Tseng CF, Chu P, Huang TY, Lin YF, Lu KC. Incidence and factors predictive of acute renal failure in patients with advanced liver cirrhosis. Clin Nephrol 2006;65:28-33.
11. Moreau R, Durand F, Poynard T, Moreau R, Durand F, Poynard T, Duhamel C, Cervoni JP, Ichaï P, Abergel A, Halimi C, Pauwels M, Bronowicki JP, Giostra E, Fleurot C, Gurnot D, Nouel O, Renard P, Rivoal M, Blanc P, Coumaros D, Ducloux S, Levy S, Pariente A, Perarnau JM, Roche J, Scribe-Outtas M, Valla D, Bernard B, Samuel D, Butel J, Hadengue A, Platek A, Lebrec D, Cadranel JF. Terlipressin in patients with cirrhosis and type 1 hepatorrenal syndrome: a retrospective multicenter study. Gastroenterology 2002; 122:923-930.
12. Ginès P, Guevara M, Arroyo V, Rodés J. hepatorrenal syndrome. Lancet 2003;362:1819-1827.
13. Schepke M, Appenrodt B, Heller J, Zielinsky J, Sauerbruch T. Prognostic factors for patients with cirrhosis and kidney dysfunction in the era of MELD: results of a prospective study. Liver international 2006;26:834-839.
14. Follo A, Llovet JM, Navasa M, Planas R, Forns X, Francitorra A, Rimola A, Gassull MA, Arroyo V, Rodés J. Renal impairment after spontaneous bacterial peritonitis in cirrosis: incidence, clinical course, predictive factors and prognosis. Hepatology 1994;20:1495-1501.
15. Sort P, Navasa M, Arroyo V, Aldeguer X, Planas R, Ruizdel-Arbol L, Castells L, Vargas V, Soriano G, Guevara M, Ginès P, Rodés J. Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis. N Engl J Med 1999;341:403-409.
16. Ruiz del Arbol L, Urman J, Fernández J, Gonzalez M, Navasa M, Monescillo A, Albillos A, Jimenez W, Arroyo V. Systemic, renal and hepatic haemodynamic derangement in cirrhotic patients with spontaneous bacterial peritonitis. Hepatology 2003;38:1210-1218.
17. Perdomo Coral G, Alves de Mattos A. Renal impairment after spontaneous bacterial peritonitis: incidence and prognosis. Can J Gastroenterol 2003;17:187-190.
18. Terra C, Guevara M, Torre A, Gilabert R, Fernández J, Martín-Llahí M, Baccaro ME, Navasa M, Bru C, Arroyo V, Rodes J, Ginés P. Renal failure in cirrhosis and sepsis unrelated to spontaneous bacterial peritonitis. Value of MELD score. Gastroenterology 2006;129:1944-1953.
19. Cardenas A, Ginès P, Uriz J Bessa X, Salmerón JM, Mas A, Ortega R, Calahorra B, De Las Heras D, Bosch J, Arroyo V, Rodés J. Renal failure alter upper gastrointestinal bleeding in cirrosis: incidente, clinical course, predictive factors, and short-term prognosis. Hepatology 2001;34:671-676.
20. Hampel H, Bynum GD, Zamora E, El-Serag HB. Risk factors for the development of renal dysfunction in hospitalized patients with cirrhosis. Am J Gastroenterol 2001;96:2206-2210.
21. Ginès A, Fernández-Esparrach G, Monescillo A, Villa C, Domenech E, Abecasis R, Angeli P, Ruiz-Del-Arbol L, Planas R, Sola R, Gines P, Terg R, Inglada L, Vaque P, Salerno F, Vargas V, Clemente G, Quer JC, Jimenez W, Arroyo V, Rodes J. Randomized trial comparing albumin, dextran 70, and polygeline in cirrhotic patients with ascites treated by paracentesis. Gastroenterology 1996;11:1002-1010.
22. Cárdenas A, Arroyo V. Mechanisms of water and sodium retention in cirrhosis and the pathogenesis of ascitis. Best practice & Research Clinical Endocrinology & Metabolism 2003;17:607-622.
23. Ginés P, Berl T, Bernardi M, Bicher DG, Hamon G, Jimenez W, Liard J, Martin P, Schrier R. Hyponatremia in cirrhosis: from pathogenesis to treatment. Hepatology 1998;28:851-864.
24. Fernandez-Esparrach G, Sanchez-Fueyo A, Ginès P, Uriz J, Quintó Ll, Ventura P, Cárdenas A, Guevara M, Sort P, Jiménez W, Bataller R, Arroyo V, Rodés J. A prognostic model for predicting survival in cirrhosis with ascites. Journal of Hepatology 2001;34:46-52.
25. Akriviadis E, Botla R, Briggs W, Han S, Reynolds T, Shakil O. Pentoxifylline improves short-term survival in severe acute alcoholic hepatitis: a double-blind, placebo-controlled trial. Gastroenterology 2000;119:1637-1648.
26. Watt K, Uhanova J, Minu K GY. hepatorrenal syndrome: diagnostic accuracy, clinical features, and outcome in a tertiary care center. Am J Gastroenterol 2002;97:2046-2050.
27. Schepke M, Roth F, Koch I, Heller J, Rabe C, Brensing KA, Schiedermaier P, Schild HH, Sauerbruch T. Prognostic impact of renal impairment and sodium imbalance in patients undergoing transjugular intrahepatic portosystemic shunting for the prevention of variceal rebleeding. Digestion 2003;67:146-153.